GW Pharma, Sage Therapeutics named Top Picks in biotech at Stifel

Sage Therapeutics Inc. said Friday its stock has been halted premarket ahead of a joint meeting of the U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee to discuss its Zulresso treatment for postpartum depression. The meeting is scheduled for 8.00 a.m. Eastern to 5.00 p.m. Shares have fallen 16.5% in 2018, while the S&P 500 has gained 2.5%.

Nov. 2, 2018 at 7:09 a.m. ET

by Ciara Linnane

Sage Therapeutics shares halted premarket for news pending

Sage Therapeutics shares halted premarket for news pending

Nov. 2, 2018 at 6:59 a.m. ET

by Ciara Linnane

Sage Therapeutics started at outperform with $170 stock price target at Oppenheimer

Sage Therapeutics started at outperform with $170 stock price target at Oppenheimer

Sage Therapeutics Inc.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
(See Full Profile)

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time.
Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.